Taylor Swift Gets Apple Music to Pay Up
On Sunday morning, Taylor Swift took Apple to task for the royalty agreement on its news music streaming service. Her open letter on Tumblr, titled “To Apple, Love Taylor,” said, “I’m sure you are aware that Apple Music will be offering a free 3 month trial to anyone who signs up for the service. I’m not sure you know that Apple Music will not be paying writers, producers, or artists for those three months. I find it to be shocking, disappointing and completely unlike this historically progressive and generous company.”
Related Link: How the Video Game Industry Is Failing Its Fans
“Three months is a long time to go unpaid, and it is unfair to ask anyone to work for nothing,” the pop singer argued on the behalf of music-makers everywhere, many of whom had voiced their discontent with the royalty policy. She concluded her letter saying, “We don’t ask you for free iPhones. Please don’t ask us to provide you with our music for no compensation.”
It was a sentiment shared by many independent music artists and producers. Just a few weeks earlier, the American Association for Independent Music had chimed in, “Since a sizable percentage of Apple’s most voracious music consumers are likely to initiate their free trials at launch, we are struggling to understand why rights holders would authorize their content on the service before October 1st.”
It took less than 24 hours for the “historically progressive and generous company” to respond via Twitter, and it didn’t wait until morning to make its announcement. Eddy Cue, Apple’s senior vice president of Internet Software and Services, personally called Swift to deliver the news before tweeting at 11:29 p.m., “#AppleMusic will pay artists for streaming, even during customers’ free trial period.”
Cue followed up with a feel-good response a minute later: “We hear you @taylorswift13 and indie artists. Love, Apple.” Later, Cue said that the company will pay artists on a per stream basis during the free trial period, although Cue declined to say what the rate would be. Once the free introductory period is over, Apple Music will pay music owners 71.5 percent of Apple Music’s overall subscription revenue in the United States.
Swift tweeted her response and addressed it to her fans and supporters: “I am elated and relieved. Thank you for your words of support today. They listened to us.”
Related Link: Apple Muscles Into Streaming Music Market
Swift’s crusade on social media showed the increasing weight that collective opinions on Twitter, Instagram and Facebook can have to force a change in corporate policy and direction. In a comic echo of that power, BuzzFeed promptly put together a list of 18 more issues Swift could fix through the power of social media, ranging from the battery life of iPhones to the size of Pringles cans.
Apple Music is launching on June 30, offering users a free, three-month subscription period. After that, the service will charge $9.99 a month for individuals and $14.99 a month for families with up to six members.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.